Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China
Pediatric Investigation · 2020-09 · 4 (3) · 157-167
DOI: 10.1002/ped4.12214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Investigation, online erschienen am 27.09.2020. Verfasst von Yan Su und 17 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Pediatric Hematology Oncology National Key Discipline of Pediatrics Ministry of Education Key Laboratory of Major Diseases …. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Importance Neuroblastoma is the most common extracranial malignant solid tumor in children. Multidisciplinary care is critical to improving the survival of pediatric patients with neuroblastoma.
Objective
To systematically summarize the clinical characteristics of children with neuroblastoma and evaluate their prognosis with multidisciplinary care provided in a single center.
Methods
This retrospective study analyzed the clinical data of 1041 patients with neuroblastoma who were diagnosed, treated, and followed‐up in the Hematology‐Oncology Center of Beijing Children’s Hospital from 2007 to 2019.
Results
The median age at diagnosis was 34 months; 80.8% of the patients were younger than 5 years of age. Notably, 243 patients (23.3%) were classified as low‐risk, 249 patients (23.9%) were classified as intermediate‐risk, and 549 (52.7%) were classified as high‐risk. Furthermore, 956 patients underwent surgical resections; 986 (94.7%) patients received chemotherapy; and 176 patients with high‐risk neuroblastoma received hematopoietic stem cell transplantation. The 5‐year event‐free survival (EFS) rate was 91.3% and 5‐year overall survival (OS) rate was 97.5% in low‐risk group; in the intermediate‐risk group, these rates were 85.1% and 96.7%, respectively, while they were 37.7% and 48.9% in the high‐risk group ( P < 0.001 for both). The 5‐year EFS and OS rates were significantly higher in patients diagnosed between 2015 and 2019 than in patients diagnosed between 2007 and 2014 ( P < 0.001). In total, 278 patients (26.7%) exhibited tumor relapse or progression; the median interval until relapse or progression was 14 months. Of the 233 patients who died, 83% died of relapse or progression of neuroblastoma and 4.3% died of therapy‐related complications.
Interpretation
The 5‐year OS rate was low in high‐risk patients, compared with low‐and intermediate‐risk patients. Multidisciplinary care is critical for improvement of survival in pediatric patients with neuroblastoma. Additional treatment strategies should be sought to improve the prognosis of patients with high‐risk neuroblastoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Key Laboratory of Pediatric Hematology Oncology National Key Discipline of Pediatrics Ministry of Education Key Laboratory of Major Diseases in Children Hematology Oncology Center Beijing Children's Hospital Cap…
- Department of Surgical Oncology Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
- Department of Thoracic Surgery Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
- Department of Otorhinolaryngology Head and Neck Surgery Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
- Imaging Center Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
- Department of Pathology Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
Zitieren
APA
Su, Y., Qin, H., Chen, C., Wang, S., Zhang, S., Zhang, D., Jin, M., Peng, Y., He, L., Wang, X., Qian, S., Qin, M., Ge, M., Zhang, F., Zeng, Q., Wang, H., Ma, X., & Ni, X. (2020). Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatric Investigation, 4(3), 157-167. https://doi.org/10.1002/ped4.12214
Vancouver
Su Y, Qin H, Chen C, Wang S, Zhang S, Zhang D, et al. Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China. Pediatric Investigation. 2020;4(3):157-167. doi:10.1002/ped4.12214
BibTeX
@article{Su2020,
author = {Su, Yan and Qin, Hong and Chen, Chenghao and Wang, Shengcai and Zhang, Shihan and Zhang, Dawei and Jin, Mei and Peng, Yun and He, Lejian and Wang, Xiaoman and Qian, Suyun and Qin, Maoquan and Ge, Ming and Zhang, Fuquan and Zeng, Qi and Wang, Huanmin and Ma, Xiaoli and Ni, Xin},
title = {Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China},
journal = {Pediatric Investigation},
year = {2020},
volume = {4},
number = {3},
pages = {157--167},
doi = {10.1002/ped4.12214}
}
EUVIMED